The Company was deeply saddened to learn of Mr. Chris van Ingen’s passing on June 27, 2017.
Mr. van Ingen served on the Company’s Board from 2012 to June 2017, and as a director of Bruker Energy & Supercon Technologies, Inc., a wholly-owned subsidiary of the Company, from 2009 to 2013. The Company’s Board and management are extremely grateful for Mr. van Ingen’s guidance and leadership over the years and extend their deepest condolences to his family.
Chris van Ingen served as an advisor to various life sciences and analytical technology companies since 2007, including Bruker and certain of its subsidiaries from 2008 until 2011. Mr. van Ingen also served as a director of Bruker Energy & Supercon Technologies, Inc. from 2009 through March 2013, including as chairman of the board of directors and member of the Compensation Committee from 2010 to March 2013. From 2001 until October 2007, he was President of the Life Sciences and Chemical Analysis Group at Agilent Technologies, Inc. Prior to joining Agilent, Mr. van Ingen was Vice President of Sales and Marketing at Hewlett Packard's Chemical Analysis Group and held other senior management positions at Hewlett Packard's Avondale Division and Netherlands Country Operation. Mr. van Ingen also served on the board of directors of Trinean N.V., a privately-held life sciences instrumentation company based in Belgium and on the board of directors of Lifeonics Limited, a privately-held life sciences company based in New Zealand. Mr. van Ingen previously served as chairman of the board of directors and as a member of Audit Committee of Accelrys, Inc. from 2010 to 2014 and served on the board of directors and Compensation Committee of Promega Corporation, a privately-held biotechnology company, from 2010 to 2015. He also served on the board of directors and Compensation Committee of ProteinSimple, a privately-held life sciences company, from March 2014 until July 2014. Mr. van Ingen held a B.S. degree in analytical chemistry. Mr. van Ingen brought to the board financial, sales and marketing, and general management experience in the analytical and life sciences industries, as well as significant experience in corporate governance, strategic planning and public company compensation matters. Most recently, Mr. van Ingen served on the Company's Audit Committee and Nominating Committee.